Cerenome, Inc. (CNSY) stock
CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3067% below fair value
$0.71+0.08 (+12.14%)
Close on Nov 18, 2026Market cap $5.36MP/E –Yield –
Cerenome operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cerenome's operating income for the twelve months ending Jun 30, 2026 was -$26.40M. For fiscal 2025 it was -$15.30M. The highest annual figure on record is -$3.66M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.30M | – |
| FY2024 | Dec 31, 2024 | -$14.70M | – |
| FY2023 | Dec 31, 2023 | -$13.32M | – |
| FY2022 | Dec 31, 2022 | -$19.71M | – |
| FY2021 | Dec 31, 2021 | -$12.49M | – |
| FY2020 | Dec 31, 2020 | -$9.58M | – |
| FY2019 | Dec 31, 2019 | -$3.66M | – |
| FY2018 | Dec 31, 2018 | -$8.76M | – |
| FY2017 | Dec 31, 2017 | -$20.68M | – |
| FY2016 | Dec 31, 2016 | -$19.71M | – |
| FY2015 | Dec 31, 2015 | -$15.29M | – |
| FY2014 | Dec 31, 2014 | -$32.44M | – |
| FY2013 | Dec 31, 2013 | -$30.68M | – |
| FY2012 | Dec 31, 2012 | -$28.42M | – |
| FY2011 | Dec 31, 2011 | -$29.41M | – |
| FY2010 | Dec 31, 2010 | -$25.32M | – |
| FY2009 | Dec 31, 2009 | -$21.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.72M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.09M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.94M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.50M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.40M | -152.1% |
| Q2 FY2020 | Jun 30, 2020 | -$2.35M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.44M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.21M | – |
| Q3 FY2019 | Sep 30, 2019 | $2.68M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.96M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.17M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.35M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.63M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.34M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.58M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.13M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.59M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.80M | – |
| Q2 FY2016 | Jun 30, 2016 | -$6.22M | – |
See a number that looks wrong?